Pharmaceutical composition for preventing or treating obesity containing biglycan as active ingredient

A proteoglycan and active ingredient technology, which can be used in medical preparations containing active ingredients, drug combinations, peptide/protein ingredients, etc. clarify issues, etc.

Pending Publication Date: 2022-01-28
KOREA UNIV RES & BUSINESS FOUND +1
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] However, the appetite-suppressing or weight-loss effects of biglycan have not been elucidated, and the efficacy of biglycan on obesity is also completely unknown

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for preventing or treating obesity containing biglycan as active ingredient
  • Pharmaceutical composition for preventing or treating obesity containing biglycan as active ingredient
  • Pharmaceutical composition for preventing or treating obesity containing biglycan as active ingredient

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0068] Example 1: Confirmation that biglycan suppresses the expression of appetite-stimulating peptide in vitro

[0069] Hypothalamic cells N41 expressing appetite-stimulating peptides, agouti-related protein (AgRP) and neuropeptide Y (NPY) (Imperatore et al., Pharmacol. Res. 111:600-609, 2016; Oh et al., Autophagy 12:2009 -2025, 2016; Sasaki et al., Endocrinology 151:2556-2566, 2010, (Cellutions Biosystems Inc., CLU121)) in DMEM containing 10% FBS and 1% penicillin-streptomycin at 37°C and 5% CO 2cultivated in an atmosphere. Then, the cells were each treated with 0 ng / ml, 10 ng / ml and 100 ng / ml biglycan, and cultured for 1 hour, 12 hours and 24 hours. The control used here was the cells treated with the solution for dissolving biglycan (0.1% BSA). Then, mRNA expression was measured using real-time PCR.

[0070] Such as figure 1 As shown, the results showed that treatment with biglycan significantly decreased the mRNA expression of the appetite-stimulating peptides AgRP an...

Embodiment 2

[0071] Example 2: Confirmation that biglycan enhances the expression of appetite-suppressing peptides in vitro

[0072] Hypothalamic cells expressing the appetite suppressant peptide proopiomelanocortin (POMC) N43 / 5 (Cai et al., J.Endocrinol.192:605-614, 2007; Cakir et al., The Journal of Biological Chemistry288:17675-17688 , 2013; Oh et al., Autophagy 12:2009-2025, 2016, (CellutionsBiosystems Inc, CLU121)) in DMEM containing 10% FBS and 1% penicillin-streptomycin at 37°C and 5% CO 2 cultivated in an atmosphere. Then, the cells were treated with 0 ng / ml, 10 ng / ml and 100 ng / ml biglycan, respectively, and cultured for 1 hour, 12 hours and 24 hours. The control used here was the cells treated with the solution for dissolving biglycan (0.1% BSA). Then, mRNA expression was measured using real-time PCR.

[0073] Such as figure 2 As shown, the results showed that treatment with biglycan significantly increased the mRNA expression of the appetite suppressant peptide POMC compare...

Embodiment 3

[0074] Example 3: Confirmation of the appetite-suppressing and weight-gain-suppressing effects of biglycan in an obesity-induced animal model

[0075] An obesity-induced animal model was generated and used to determine the role of biglycan in suppressing appetite and weight gain.

[0076] First, nine mice (C57BL / 6J males) were fed a high-fat diet (HFD) for 4 weeks to generate an obesity-induced animal model.

[0077] A biglycan-administered group was generated by intraperitoneally administering biglycan to each mouse once every two days at a dose of 1 mg / kg body weight.

[0078] Four weeks after induction of obesity, the difference between the high-fat diet (HFD) group and the high-fat diet group (BGN) administered with biglycan (biglycan was administered at a dose of 1 mg / Kg body weight) was measured. Difference in weight gain ( image 3 A). The final body weight of the biglycan-administered group (BGN) was significantly lower than that of the high-fat diet group (HFD) ( ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a pharmaceutical composition which is for preventing or treating obesity, and contains biglycan as an active ingredient. Biglycan according to the present invention induces appetite suppression by suppressing the expression of Agrp and NPY, which are appetite promoting peptides, and increasing the expression of POMC, which is an appetite suppressing peptide, and thus is very useful as a medicine for treating obesity.

Description

【Technical field】 [0001] The present invention relates to a pharmaceutical composition containing biglycan for the prevention or treatment of obesity, and more particularly to a bisaminoglycan capable of suppressing appetite by suppressing the expression of appetite-promoting peptide or promoting the expression of appetite-suppressing peptide. Use of glycan for the prevention or treatment of obesity. 【Background technique】 [0002] Obesity is caused by excess energy accumulation due to a regulatory imbalance between energy intake and expenditure, and given that obesity can lead to cardiovascular diseases including hyperlipidemia, diabetes, arteriosclerosis, and hypertension, The fact that it is a serious disease and is therefore considered a disease that is not merely a metabolic disorder or a risk factor for the disease (Mantzoros et al., J. Clin. Endocrinol. Metab., 85:4000-2, 2000). [0003] Efforts to treat obesity continue, and in addition to exercise therapy and dieti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/16A61P3/04A23L33/17
CPCA23L33/17A61K38/16A61P3/04A23V2002/00A23V2200/332
Inventor 金贤洙金恩敬金雪松
Owner KOREA UNIV RES & BUSINESS FOUND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap